- Home
- COLL
as of 12-17-2025 3:38pm EST
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | STOUGHTON |
| Market Cap: | 1.5B | IPO Year: | 2015 |
| Target Price: | $47.50 | AVG Volume (30 days): | 531.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.63 | EPS Growth: | -24.84 |
| 52 Week Low/High: | $23.23 - $49.49 | Next Earning Date: | 11-06-2025 |
| Revenue: | $757,067,000 | Revenue Growth: | 26.34% |
| Revenue Growth (this year): | 26.35% | Revenue Growth (next year): | 3.67% |
Stock Insider Trading Activity of Collegium Pharmaceutical Inc. (COLL)
EVP & Chief Commercial Officer
Avg Cost/Share
$48.28
Shares
17,600
Total Value
$847,855.20
Owned After
110,088
Director
Avg Cost/Share
$47.03
Shares
3,650
Total Value
$171,673.37
Owned After
52,629
SEC Form 4
Director
Avg Cost/Share
$47.21
Shares
34,853
Total Value
$1,645,535.60
Owned After
64,634
SEC Form 4
EVP & Chief Financial Officer
Avg Cost/Share
$40.83
Shares
30,000
Total Value
$1,215,753.34
Owned After
131,525
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Dreyer Scott | COLL | EVP & Chief Commercial Officer | Dec 8, 2025 | Sell | $48.28 | 17,600 | $847,855.20 | 110,088 | |
| Balice-Gordon Rita J. | COLL | Director | Dec 5, 2025 | Sell | $47.03 | 3,650 | $171,673.37 | 52,629 | |
| Fallon John A. | COLL | Director | Nov 12, 2025 | Sell | $47.21 | 34,853 | $1,645,535.60 | 64,634 | |
| Tupper Colleen | COLL | EVP & Chief Financial Officer | Nov 6, 2025 | Sell | $40.83 | 30,000 | $1,215,753.34 | 131,525 |
Compare COLL vs Leading Stocks
See how COLL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "COLL Collegium Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.